Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease

Reuters Staff  |  Issue: November 2019  |  

Side effects led to a permanent reduction in dose among 33.1% of nintedanib patients compared with 4.2% of those getting placebo.

“The use of nintedanib may slow the disease progression, but our challenge for the future is to design studies that identify earlier targets to prevent the establishment of this still highly morbid condition,” Dr. Goldberg says.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019 Sep 29. [Epub ahead of print]
  2. Goldberg HJ. Understanding progressive fibrosing interstitial lung disease through therapeutic trials. N Engl J Med. 2019 Sep 29. [Epub ahead of print]

Related Articles

    FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

    The U.S. Food & Drug Admin­istration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in…

    Advances in Connective Tissue Disease-Associated Interstitial Lung Disease

    ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of…